ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.
生物技术公司ProMIS Neurosciences Inc.（纳斯达克代码：PMN）专注于生成和开发针对神经退行性疾病中的有毒错误折叠蛋白的治疗药物。今天宣布，ProMIS Neurosciences的临时首席执行官Neil Warma和ProMIS Neurosciences的首席医疗官Larry Altstiel万.D.博士将在2024年8月6日下午12:00 ET参加BTIG虚拟生物技术会议的炉边聊天。
A live webcast of the fireside chat will be available to conference participants.
现场网络直播将向与会者提供。
About ProMIS Neurosciences Inc.
关于ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.
ProMIS神经科学公司是一家临床阶段的生物技术公司，专注于生成和开发抗体治疗，有选择地针对神经变性疾病如阿尔茨海默病（AD）、肌萎缩性侧索硬化（ALS）和多系统萎缩（MSA）中的有毒错折蛋白质。该公司的专有目标发现引擎采用热力学、计算发现平台- ProMIS和Collective Coordinates-在误折的蛋白质的分子表面上预测新的目标，被称为特异性疾病表位。利用这种独特的方法，该公司正在开发针对AD、ALS和MSA的新型抗体治疗方法。ProMIS在安大略省的多伦多和马萨诸塞州的剑桥设有办事处。
For further information:
进一步了解：
Visit us at
请访问我们的网址
Please submit media inquiries to info@promisneurosciences.com.
请将媒体查询提交至info@promisneurosciences.com。
For Investor Relations, please contact:
Precision AQ
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
如需投资者关系，请联系：
Josh.Rappaport@precisionaq.com
Anne Marie Fields，董事总经理
annemarie.fields@precisionaq.com
电话：212-362-1200